Unlike previous JNCs (1 to 7), JNC8 does not provide a comprehensive review of the epidemiologic status of hypertension in the United States, nor does it emphasize overall risk, nor refine diagnosis and classification, but instead addresses 3 important questions about the control of hypertension with the primary target of the overall prognostic health benefit of hypertensive patients, making 9 recommendations. 1, To answer these 3 questions (e.g., question 1: initiation of blood pressure lowering thresholds), the JNC8 committee used only randomized controlled trials (RCTs) as the primary literature review (excluding meta-analyses and observational studies), but of the 11 recommendations included in the recommendations, 2 were strong evidence (Class A evidence), 2 were Class B evidence, 1 was Class C evidence, and 6 were Class E evidence (expert’s recommendations). This brings a thought that: are the recommendations of JNC8 mainly based on evidence or on the opinions of experts? Are these recommendations really authoritative and practicable? This point remains to be discussed and debated. 2. Target blood pressure values? In this regard JNC8 is consistent with the ASH/ISH community clinical practice guidelines and the AHA/ACC/CDC scientific recommendations for blood pressure management. The target blood pressure for blood pressure control has been relaxed to <140/90 mm Hg for all hypertensive populations except the elderly. the advantage of this target blood pressure facilitates easier manipulation by physicians, especially community physicians. A possible problem with it is that for some patients who need the benefit of lower blood pressure, physicians will no longer make the effort to combine drug therapy to bring blood pressure down further. Since JNC8 does not address specific types of hypertension (heart failure, coronary artery disease, stroke, refractory hypertension, etc.), it needs to be thought about and continuously explored whether such relaxed blood pressure target values can benefit all hypertensive patients. 3. In terms of the selection of antihypertensive drugs, JNC8 proposed 4 classes of drugs (thiazide diuretics, CCB, ACEI and ARB), excluding β-blockers from conventional drug therapy, and the RCT on which the exclusion of β-blockers was based was only the LIEF study, and we also know that the hypertensive patients enrolled in the LIEF study itself were the hypertensive population with left ventricular hypertrophy, and the main The main beta-blocker used was atenolol, while >60% of patients were combined with diuretics. This trial was inherently controversial in terms of drug selection and drug combinations, and JNC8 did not address the hypertensive population with coronary artery disease and heart failure, which are the primary appropriate populations for β-blockers. In recent decades, β-blocker R&D and application have developed significantly, and β-blockers with vasodilator effect have been widely used in clinical treatment, so it is worth thinking whether β-blockers should be excluded. 4. Another feature of JNC8 in drug treatment is based on the difference of ethnicity, which is divided into black and non-black people to treat them differently. The United States is a multiracial country, and the proportion of blacks is relatively high, and the increase of blood pressure in blacks is more likely to produce target organ damage, and the sensitivity to RASI treatment is slightly lower. China is a non-black race, and Chinese hypertensive patients also have their own characteristics, the proportion of high salt intake, combined with abnormal glucose and lipid metabolism is increasing year by year, and China is a large country of stroke, 85% of the causes of death in stroke are from poor blood pressure control, so we can learn from the ideas of JNC8, but should be based on the characteristics of Chinese hypertension and hypertension guidelines for effective hypertension management, not only to consider We should consider not only the blood pressure level but also the overall cardiovascular risk, prioritize the best individualized treatment according to the hypertensive characteristics of the Chinese population, improve blood pressure monitoring, manage the patient’s compliance, and consider the ultimate benefit of treatment for hypertensive patients in all aspects.